Fierce Biotech

Novartis pens $2B deal for allergy biotech with potential Xolair successor

Published

2 weeks ago

on

March 27, 2026

By

Temp User

Novartis has penned a $2 billion deal for a biotech whose next-gen anti-IgE program could offer a worthy successor to Xolair.

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

The old and New Edition cast comes together to perform
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State

Exit mobile version